StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3033% below fair value
$79.32−0.87 (-1.08%)

Close on Nov 20, 2026Market cap $29.58BP/E 31.2Yield –

DexCom free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

DexCom's free cash flow for the twelve months ending Sep 30, 2026 was $1.10B, up 3.4% year over year. For fiscal 2025 it was $1.08B, up 70.8% from the year before. Over ten years it grew 52.6% a year on average. The highest annual figure on record is $1.08B in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.08B+70.8%
FY2024Dec 31, 2024$630.70M+23.2%
FY2023Dec 31, 2023$511.90M+68.0%
FY2022Dec 31, 2022$304.70M+471.7%
FY2021Dec 31, 2021$53.30M-80.7%
FY2020Dec 31, 2020$276.60M+105.7%
FY2019Dec 31, 2019$134.50M+139.8%
FY2018Dec 31, 2018$56.10M+115.8%
FY2017Dec 31, 2017$26.00M+5100.0%
FY2016Dec 31, 2016$500.00K-96.8%
FY2015Dec 31, 2015$15.70M+112.2%
FY2014Dec 31, 2014$7.40M–
FY2013Dec 31, 2013-$5.50M–
FY2012Dec 31, 2012-$42.60M–
FY2011Dec 31, 2011-$38.10M–
FY2010Dec 31, 2010-$49.60M–
FY2009Dec 31, 2009-$42.38M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$272.70M-52.9%
Q2 FY2026Jun 30, 2026$184.50M-11.7%
Q1 FY2026Mar 31, 2026$449.00M+363.8%
Q4 FY2025Dec 31, 2025$192.10M+8.7%
Q3 FY2025Sep 30, 2025$579.40M+556.2%
Q2 FY2025Jun 30, 2025$208.90M-2.1%
Q1 FY2025Mar 31, 2025$96.80M-36.4%
Q4 FY2024Dec 31, 2024$176.80M+118.0%
Q3 FY2024Sep 30, 2024$88.30M-59.6%
Q2 FY2024Jun 30, 2024$213.30M+62.5%
Q1 FY2024Mar 31, 2024$152.30M+88.7%
Q4 FY2023Dec 31, 2023$81.10M+17.5%
Q3 FY2023Sep 30, 2023$218.80M+18.3%
Q2 FY2023Jun 30, 2023$131.30M+61.5%
Q1 FY2023Mar 31, 2023$80.70M–
Q4 FY2022Dec 31, 2022$69.00M+169.5%
Q3 FY2022Sep 30, 2022$185.00M+32.9%
Q2 FY2022Jun 30, 2022$81.30M–
Q1 FY2022Mar 31, 2022-$30.60M–
Q4 FY2021Dec 31, 2021$25.60M-77.1%
Q3 FY2021Sep 30, 2021$139.20M+38.9%
Q2 FY2021Jun 30, 2021-$39.60M-141.3%
Q1 FY2021Mar 31, 2021-$71.90M–
Q4 FY2020Dec 31, 2020$111.80M+12.2%
Q3 FY2020Sep 30, 2020$100.20M+123.7%
Q2 FY2020Jun 30, 2020$95.90M+444.9%
Q1 FY2020Mar 31, 2020-$31.30M–
Q4 FY2019Dec 31, 2019$99.60M+522.5%
Q3 FY2019Sep 30, 2019$44.80M+35.8%
Q2 FY2019Jun 30, 2019$17.60M-43.4%
Q1 FY2019Mar 31, 2019-$27.50M–
Q4 FY2018Dec 31, 2018$16.00M-32.2%
Q3 FY2018Sep 30, 2018$33.00M+45.4%
Q2 FY2018Jun 30, 2018$31.10M+1252.2%
Q1 FY2018Mar 31, 2018-$24.00M–
Q4 FY2017Dec 31, 2017$23.60M–
Q3 FY2017Sep 30, 2017$22.70M–
Q2 FY2017Jun 30, 2017$2.30M–
Q1 FY2017Mar 31, 2017-$22.60M–
Q4 FY2016Dec 31, 2016-$4.30M–

More DexCom figures

See a number that looks wrong?